Olanzapine Dosing, Titration, and Monitoring for Acute Psychosis

Starting Dose and Target Range

• International early‑psychosis guidelines recommend an initial target dose of 7.5–10 mg once daily for adults presenting with acute psychosis, with titration to the target within several days. 1
• In frail or older non‑smoking female patients, a lower starting dose of 5 mg once daily is advised to reduce hypotensive and metabolic risks. 4

Titration Strategy

• Dose adjustments should be made no more frequently than once per week, reflecting the ≈1‑week time required to reach steady‑state plasma concentrations. 1
• For early‑psychosis patients, dose increases are recommended only after 14–21 days of the previous dose if clinical response remains inadequate. 1

Assessment of Therapeutic Response

• A minimum trial of 4–6 weeks at a therapeutic dose is required before declaring treatment failure. 5
• If positive symptoms persist after 4 weeks of adequate dosing with confirmed adherence, clinicians should re‑evaluate the diagnosis and consider switching to an alternative antipsychotic. 1
• After two unsuccessful trials of first‑line atypical antipsychotics (≈12 weeks total), initiation of clozapine is recommended. 6

Baseline Evaluations Before Initiation

• Record the target symptom domains to be monitored during treatment. 5
• Obtain baseline metabolic parameters (weight, body‑mass index, waist circumference, blood pressure, fasting glucose, lipid panel). 6
• Perform a baseline electrocardiogram when cardiac risk factors are present. 5
• Conduct a pregnancy test in women of child‑bearing potential. 4

Ongoing Monitoring

Metabolic Surveillance

• Fasting glucose and lipid profile: baseline, week 12, then annually (more often if abnormalities are detected). 6
• Blood pressure: baseline, week 12, then annually. 4

Side‑Effect Monitoring

• Extrapyramidal symptoms (EPS): assess at every visit; olanzapine carries a lower EPS risk than typical antipsychotics. 1
• Tardive dyskinesia: use standardized tools (e.g., AIMS) at baseline and at least every 6 months. 6

Clinical Considerations

Avoiding Common Pitfalls

• Do not prescribe prophylactic anticholinergic agents for EPS, as olanzapine’s low EPS risk makes them unnecessary and they may impair cognition. 1
• For first‑episode psychosis, prioritize the lower dose range (7.5–10 mg/day) to minimize metabolic side effects and improve adherence. 1

Maintenance Therapy

• After achieving symptom stabilization, continue olanzapine at the effective dose for at least 1–2 years following the first episode. 5
• The American Psychiatric Association advises maintaining the same antipsychotic that produced improvement, with periodic reassessment and possible dose reduction during stable periods. 6

Metabolic Risk Mitigation

• Consider adding metformin to attenuate olanzapine‑associated weight gain, especially in younger patients or those with high metabolic risk. 4